Keren Regev1, Brian C Healy2, Fariha Khalid3, Anu Paul1, Renxin Chu3, Shahamat Tauhid3, Subhash Tummala3, Camilo Diaz-Cruz4, Radhika Raheja1, Maria A Mazzola1, Felipe von Glehn1, Pia Kivisakk1, Sheena L Dupuy3, Gloria Kim3, Tanuja Chitnis3, Howard L Weiner3, Roopali Gandhi1, Rohit Bakshi5. 1. Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. 2. Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts2Biostatistics Center, Massachusetts General Hospital, Boston. 3. Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts3Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. 4. Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. 5. Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts3Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts4Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Abstract
Importance: MicroRNAs (miRNAs) are promising multiple sclerosis (MS) biomarkers. Establishing the association between miRNAs and magnetic resonance imaging (MRI) measures of disease severity will help define their significance and potential impact. Objective: To correlate circulating miRNAs in the serum of patients with MS to brain and spinal MRI. Design, Setting, and Participants: A cross-sectional study comparing serum miRNA samples with MRI metrics was conducted at a tertiary MS referral center. Two independent cohorts (41 and 79 patients) were retrospectively identified from the Comprehensive Longitudinal Investigation of Multiple Sclerosis at the Brigham and Women's Hospital. Expression of miRNA was determined by locked nucleic acid-based quantitative real-time polymerase chain reaction. Spearman correlation coefficients were used to test the association between miRNA and brain lesions (T2 hyperintense lesion volume [T2LV]), the ratio of T1 hypointense lesion volume [T1LV] to T2LV [T1:T2]), brain atrophy (whole brain and gray matter), and cervical spinal cord lesions (T2LV) and atrophy. The study was conducted from December 2013 to April 2016. Main Outcomes and Measures: miRNA expression. Results: Of the 120 patients included in the study, cohort 1 included 41 participants (7 [17.1%] men), with mean (SD) age of 47.7 (9.5) years; cohort 2 had 79 participants (26 [32.9%] men) with a mean (SD) age of 43.0 (7.5) years. Associations between miRNAs and MRIs were both protective and pathogenic. Regarding miRNA signatures, a topographic specificity differed for the brain vs the spinal cord, and the signature differed between T2LV and atrophy/destructive measures. Four miRNAs showed similar significant protective correlations with T1:T2 in both cohorts, with the highest for hsa.miR.143.3p (cohort 1: Spearman correlation coefficient rs = -0.452, P = .003; cohort 2: rs = -0.225, P = .046); the others included hsa.miR.142.5p (cohort 1: rs = -0.424, P = .006; cohort 2: rs = -0.226, P = .045), hsa.miR.181c.3p (cohort 1: rs = -0.383, P = .01; cohort 2: rs = -0.222, P = .049), and hsa.miR.181c.5p (cohort 1: rs = -0.433, P = .005; cohort 2: rs = -0.231, P = .04). In the 2 cohorts, hsa.miR.486.5p (cohort 1: rs = 0.348, P = .03; cohort 2: rs = 0.254, P = .02) and hsa.miR.92a.3p (cohort 1: rs = 0.392, P = .01; cohort 2: rs = 0.222, P = .049) showed similar significant pathogenic correlations with T1:T2; hsa.miR.375 (cohort 1: rs = -0.345, P = .03; cohort 2: rs = -0.257, P = .022) and hsa.miR.629.5p (cohort 1: rs = -0.350, P = .03; cohort 2: rs = -0.269, P = .02) showed significant pathogenic correlations with brain atrophy. Although we found several miRNAs associated with MRI outcomes, none of these associations remained significant when correcting for multiple comparisons, suggesting that further validation of our findings is needed. Conclusions and Relevance: Serum miRNAs may serve as MS biomarkers for monitoring disease progression and act as surrogate markers to identify underlying disease processes.
Importance: MicroRNAs (miRNAs) are promising multiple sclerosis (MS) biomarkers. Establishing the association between miRNAs and magnetic resonance imaging (MRI) measures of disease severity will help define their significance and potential impact. Objective: To correlate circulating miRNAs in the serum of patients with MS to brain and spinal MRI. Design, Setting, and Participants: A cross-sectional study comparing serum miRNA samples with MRI metrics was conducted at a tertiary MS referral center. Two independent cohorts (41 and 79 patients) were retrospectively identified from the Comprehensive Longitudinal Investigation of Multiple Sclerosis at the Brigham and Women's Hospital. Expression of miRNA was determined by locked nucleic acid-based quantitative real-time polymerase chain reaction. Spearman correlation coefficients were used to test the association between miRNA and brain lesions (T2 hyperintense lesion volume [T2LV]), the ratio of T1 hypointense lesion volume [T1LV] to T2LV [T1:T2]), brain atrophy (whole brain and gray matter), and cervical spinal cord lesions (T2LV) and atrophy. The study was conducted from December 2013 to April 2016. Main Outcomes and Measures: miRNA expression. Results: Of the 120 patients included in the study, cohort 1 included 41 participants (7 [17.1%] men), with mean (SD) age of 47.7 (9.5) years; cohort 2 had 79 participants (26 [32.9%] men) with a mean (SD) age of 43.0 (7.5) years. Associations between miRNAs and MRIs were both protective and pathogenic. Regarding miRNA signatures, a topographic specificity differed for the brain vs the spinal cord, and the signature differed between T2LV and atrophy/destructive measures. Four miRNAs showed similar significant protective correlations with T1:T2 in both cohorts, with the highest for hsa.miR.143.3p (cohort 1: Spearman correlation coefficient rs = -0.452, P = .003; cohort 2: rs = -0.225, P = .046); the others included hsa.miR.142.5p (cohort 1: rs = -0.424, P = .006; cohort 2: rs = -0.226, P = .045), hsa.miR.181c.3p (cohort 1: rs = -0.383, P = .01; cohort 2: rs = -0.222, P = .049), and hsa.miR.181c.5p (cohort 1: rs = -0.433, P = .005; cohort 2: rs = -0.231, P = .04). In the 2 cohorts, hsa.miR.486.5p (cohort 1: rs = 0.348, P = .03; cohort 2: rs = 0.254, P = .02) and hsa.miR.92a.3p (cohort 1: rs = 0.392, P = .01; cohort 2: rs = 0.222, P = .049) showed similar significant pathogenic correlations with T1:T2; hsa.miR.375 (cohort 1: rs = -0.345, P = .03; cohort 2: rs = -0.257, P = .022) and hsa.miR.629.5p (cohort 1: rs = -0.350, P = .03; cohort 2: rs = -0.269, P = .02) showed significant pathogenic correlations with brain atrophy. Although we found several miRNAs associated with MRI outcomes, none of these associations remained significant when correcting for multiple comparisons, suggesting that further validation of our findings is needed. Conclusions and Relevance: Serum miRNAs may serve as MS biomarkers for monitoring disease progression and act as surrogate markers to identify underlying disease processes.
Authors: L Truyen; J H van Waesberghe; M A van Walderveen; B W van Oosten; C H Polman; O R Hommes; H J Adèr; F Barkhof Journal: Neurology Date: 1996-12 Impact factor: 9.910
Authors: J C J Bot; F Barkhof; C H Polman; G J Lycklama à Nijeholt; V de Groot; E Bergers; H J Ader; J A Castelijns Journal: Neurology Date: 2004-01-27 Impact factor: 9.910
Authors: Ajai Tripathi; Christina Volsko; Jessie P Garcia; Eneritz Agirre; Kevin C Allan; Paul J Tesar; Bruce D Trapp; Goncalo Castelo-Branco; Fraser J Sim; Ranjan Dutta Journal: Cell Rep Date: 2019-10-22 Impact factor: 9.423
Authors: María I Dominguez-Mozo; Ignacio Casanova; Laura De Torres; Yolanda Aladro-Benito; Silvia Perez-Perez; Angel Garcia-Martínez; Patricia Gomez; Sara Abellan; Esther De Antonio; Carlos Lopez-De-Silanes; Roberto Alvarez-Lafuente Journal: Front Immunol Date: 2022-06-14 Impact factor: 8.786
Authors: Syed Z Imam; Zhen He; Elvis Cuevas; Hector Rosas-Hernandez; Susan M Lantz; Sumit Sarkar; James Raymick; Bonnie Robinson; Joseph P Hanig; David Herr; Denise MacMillan; Aaron Smith; Serguei Liachenko; Sherry Ferguson; James O'Callaghan; Diane Miller; Christopher Somps; Ingrid D Pardo; William Slikker; Jennifer B Pierson; Ruth Roberts; Binsheng Gong; Weida Tong; Michael Aschner; Mary J Kallman; David Calligaro; Merle G Paule Journal: Exp Biol Med (Maywood) Date: 2017-11-06
Authors: Joseph M Gullett; Zhaoyi Chen; Andrew O'Shea; Maisha Akbar; Jiang Bian; Asha Rani; Eric C Porges; Thomas C Foster; Adam J Woods; Francois Modave; Ronald A Cohen Journal: Neurobiol Aging Date: 2020-08-03 Impact factor: 4.673
Authors: Saumya Das; K Mark Ansel; Markus Bitzer; Xandra O Breakefield; Alain Charest; David J Galas; Mark B Gerstein; Mihir Gupta; Aleksandar Milosavljevic; Michael T McManus; Tushar Patel; Robert L Raffai; Joel Rozowsky; Matthew E Roth; Julie A Saugstad; Kendall Van Keuren-Jensen; Alissa M Weaver; Louise C Laurent Journal: Cell Date: 2019-04-04 Impact factor: 66.850
Authors: Keren Regev; Brian C Healy; Anu Paul; Camilo Diaz-Cruz; Maria Antonietta Mazzola; Radhika Raheja; Bonnie I Glanz; Pia Kivisäkk; Tanuja Chitnis; Maja Jagodic; Fredrik Piehl; Tomas Olsson; Mohsen Khademi; Stephen Hauser; Jorge Oksenberg; Samia J Khoury; Howard L Weiner; Roopali Gandhi Journal: Neurol Neuroimmunol Neuroinflamm Date: 2018-08-20
Authors: Camille A Juźwik; Sienna Drake; Marc-André Lécuyer; Radia Marie Johnson; Barbara Morquette; Yang Zhang; Marc Charabati; Selena M Sagan; Amit Bar-Or; Alexandre Prat; Alyson E Fournier Journal: Sci Rep Date: 2018-09-07 Impact factor: 4.379
Authors: Christopher C Hemond; Brian C Healy; Shahamat Tauhid; Maria A Mazzola; Francisco J Quintana; Roopali Gandhi; Howard L Weiner; Rohit Bakshi Journal: Neurol Neuroimmunol Neuroinflamm Date: 2019-02-14